A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients

Inclusion Criteria: * Age ≥ 50 years * Patients with vascular cognitive impairment according to modified Fazekas scale grade 2\~3 and/or more than 3 of lacunar infarction in Supratentorial * Patients with Clinical Deterioration Rating(CDR) score of 0.5 * Patients with Korean-Montreal Cognitive Assessment (K-MoCA) score of 23 or less * Walk or move using walking aids (i.e., walkers, walking sticks or wheelchairs) * Written informed consent Exclusion Criteria: * Clinical diagnosis of dementia (including secondary dementia due to Alzheimer's disease, vascular dementia, infections of the central nervous system (e.g., HIV, syphilis), Creutzfeld-Jacob disease, Pixie disease, Huntington's disease, Parkinson's disease, etc.) * Medication of dementia within the past 3 months. (e.g., donepezil, galantamine, rivastigmine, memantine) * Medication of brain functional improvement medication within the past 6 weeks. (e.g., citicoline, oxiracetam, piracetam, choline alfoscerate, Nicergoline, Nimodipine, ginko-biloba, acetyl-l carnitine) * No studies (no regular school entrance), illiteracy * Stroke within the past 3 months * Abnormal results from Vitamin B12, Thyroid Stimulated Hormone Test (TSH), HIV-Ab, and VDRL test contribute to or contribute to cognitive impairment of the subject * Serious mental disorders such as severe depression, schizophrenia, alcoholism, drug dependence, etc. * Severe cardiovascular disease such as myocardial infarction, unstable angina or heart failure within the past 6 months